Paclitaxel Palaver: Physicians Dissect Lessons Of Discredited Safety Warning

During a Monday webinar, interventionalists discussed the recent paclitaxel safety scare, as well as what it might say about the future of device research.

"Lessons Learned" written on chalkboard surrounded by office supplies.
• Source: Shutterstock

As a trade group for endovascular specialists, VIVA has been at the ground level for the controversy around the safety of paclitaxel-coated balloons and stents in treating patients with peripheral artery disease (PAD).

And now that the concerns have been put to rest, VIVA physicians are coming together to discuss what they’ve learned...

More from Regulation

More from Policy & Regulation